| Symbol | LPCN |
|---|---|
| Name | LIPOCINE INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 675 ARAPEEN DRIVE,SUITE 202, SALT LAKE CITY, Utah, 84108, United States |
| Telephone | +1 801 994-7383 |
| Fax | — |
| — | |
| Website | https://www.lipocine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001535955 |
| Description | Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other products in the pipeline such as LPCN 1144 LPCN 1148 and LPCN 1107. Additional info from NASDAQ: |
Director Patel Mahesh V. 🟢 acquired 52.8K shares (1 derivative) of Lipocine Inc. (LPCN) at $2.49 Transaction Date: Jun 29, 2026 | Filing ID: 031377
Read moreNew Form S-8 - Lipocine Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001493152-26-027923 <b>Size:</b> 219 KB
Read moreDirector Higuchi John W. 🟢 acquired 1.8K shares (1 derivative) of Lipocine Inc. (LPCN) at $2.19 Transaction Date: Jun 03, 2026 | Filing ID: 027262
Read moreDirector Jene Jill M. 🟢 acquired 1.8K shares (1 derivative) of Lipocine Inc. (LPCN) at $2.19 Transaction Date: Jun 03, 2026 | Filing ID: 027261
Read moreDirector Ono Richard Dana 🟢 acquired 1.8K shares (1 derivative) of Lipocine Inc. (LPCN) at $2.19 Transaction Date: Jun 03, 2026 | Filing ID: 027259
Read more(90% Positive) LIPOCINE INC. (LPCN) Announces Clinical Development Update
Read more(90% Positive) LIPOCINE INC. (LPCN) Provides Update on selected for clinical psychopharmacology research
Read moreLipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06979544 | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Seve… | Phase3 | Depression, Postpartum | Completed | 2025-06-16 | 2026-02-17 | ClinicalTrials.gov |
| NCT04874350 | A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in M… | Phase2 | Liver Cirrhosis | Completed | 2021-11-30 | 2023-12-18 | ClinicalTrials.gov |
| NCT04685993 | A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed t… | Phase2 | NASH - Nonalcoholic Steatohepatitis | Completed | 2020-11-11 | 2022-03-01 | ClinicalTrials.gov |
| NCT04134091 | The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalc… | Phase2 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2019-08-27 | 2021-06-24 | ClinicalTrials.gov |
| NCT03868059 | Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN… | Phase3 | Hypogonadism, Male | Completed | 2018-04-30 | 2019-02-21 | ClinicalTrials.gov |
| NCT03242408 | Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) | Phase3 | Hypogonadism, Male | Completed | 2017-01-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT03242590 | Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). | Phase3 | Hypogonadism, Male | Completed | 2016-12-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02081300 | Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonad… | Phase3 | Male Hypogonadism | Completed | 2014-02-01 | 2015-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| LPCN 1144 | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04685993 |
| Topical testosterone gel 1.62 % | Other | Phase PHASE3 | Male Hypogonadism | COMPLETED | NCT02081300 |
| Oral testosterone undecanoate, LPCN 1021 | Other | Phase PHASE3 | Male Hypogonadism | COMPLETED | NCT02081300 |
| LPCN 1021 | Other | Phase PHASE3 | Hypogonadism, Male | COMPLETED | NCT03242590 |
| LPCN 1021 | Other | Phase PHASE3 | Hypogonadism, Male | COMPLETED | NCT03242408 |
| LPCN 1021 | Other | Phase PHASE3 | Hypogonadism, Male | COMPLETED | NCT03868059 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT04134091 |
| LPCN 1144 Formulation B | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT04134091 |
| LPCN 1144 Formulation A | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT04134091 |
| Placebo | Other | Phase PHASE2 | Liver Cirrhosis | COMPLETED | NCT04874350 |
| LPCN 1148 | Other | Phase PHASE2 | Liver Cirrhosis | COMPLETED | NCT04874350 |
| Placebo | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT06979544 |
| LPCN 1154A | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT06979544 |
| LPCN 1154A | DRUG | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT06979544 |
| LPCN 1148 | DRUG | Phase PHASE2 | Liver Cirrhosis | COMPLETED | NCT04874350 |
| LPCN 1144 | DRUG | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04685993 |
| Placebo | DRUG | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT06979544 |
| LPCN 1144 Formulation B | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT04134091 |
| LPCN 1144 Formulation A | DRUG | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT04134091 |
| LPCN 1021 | DRUG | Phase PHASE3 | Hypogonadism, Male | COMPLETED | NCT03868059 |
| Topical testosterone gel 1.62 % | DRUG | Phase PHASE3 | Male Hypogonadism | COMPLETED | NCT02081300 |
| Oral testosterone undecanoate, LPCN 1021 | DRUG | Phase PHASE3 | Male Hypogonadism | COMPLETED | NCT02081300 |